As filed with the Securities and Exchange Commission on September 3, 2026

Registration No. 333-293906

Registration No. 333-285478

Registration No. 333-281477

Registration No. 333-279354

Registration No. 333-274234

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-8 REGISTRATION STATEMENT NO. 333-293906

FORM S-8 REGISTRATION STATEMENT NO. 333-285478

FORM S-8 REGISTRATION STATEMENT NO. 333-281477

FORM S-8 REGISTRATION STATEMENT NO. 333-279354

FORM S-8 REGISTRATION STATEMENT NO. 333-274234

UNDER

THE SECURITIES ACT OF 1933

---

APOGEE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

---

APOGEE THERAPEUTICS, INC. 2023 EQUITY INCENTIVE PLAN

APOGEE THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN

NON-PLAN STOCK OPTION GRANT

(Full title of the plans)

 Perry C. Siatis

Executive Vice President, General Counsel and Secretary

AbbVie Inc.

1 North Waukegan Road

North Chicago, Illinois 60064

(Name and address of agent for service)

(847) 932-7900

(Telephone Number of Agent for Service)

---

Copy to:

Krishna Veeraraghavan

Benjamin Goodchild

Paul, Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, New York 10019-6064

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

---

DEREGISTRATION OF SECURITIES

These Post-Effective Amendments (the “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (the “Registration Statements”) filed by Apogee Therapeutics, Inc. (“Apogee”) with the Securities and Exchange Commission (the “SEC”):

On September 3, 2026, Andor Merger Co. (“Merger Sub”), a Delaware corporation and a wholly owned subsidiary of Andor LLC (“Parent”), a Delaware limited liability company, completed its merger (the “Merger”) with and into Apogee pursuant to the terms of the Agreement and Plan of Merger, dated June 18, 2026 (the “Merger Agreement”), among Apogee, Parent, Merger Sub and, solely for the limited purposes set forth therein, AbbVie Inc. (“AbbVie”), a Delaware corporation. Apogee was the surviving corporation in the Merger and, as a result, is now an indirect wholly owned subsidiary of AbbVie.

As a result of the Merger, all offerings and sales of securities pursuant to the Registration Statements have been terminated. In accordance with an undertaking made by Apogee in Part II of each Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance under the Registration Statements that remain unsold at the termination of such offerings, Apogee hereby removes and withdraws from registration any and all of such securities registered but remaining unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and Apogee hereby terminates the effectiveness of the Registration Statements. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by Apogee pursuant to the Registration Statements.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to Apogee’s Current Report on Form 8-K filed with the SEC on June 22, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements described above to be signed on its behalf by the undersigned, thereunto duly authorized, in North Chicago, Illinois, on September 3, 2026.

No other person is required to sign these Post-Effective Amendments in reliance on Rule 478 of the Securities Act of 1933.

---